Upper urinary tract transitional cell carcinoma: is there a best?

Abstract:

BACKGROUND:This study aimed to determine the prognostic and risk factors for bladder and systemic recurrence after nephroureterectomy (NU) in patients with upper urinary tract (UUT) transitional cell carcinoma (TCC). PATIENTS AND METHODS:Data from 101 patients with nonmetastatic UUT TCC who underwent NU between 1987 and 2009 were retrospectively evaluated. Kaplan-Meier curves for sex, age, anemia, smoking, stone disease, or history of bladder tumor, primary tumor localization, multiplicity, and disease stage and grade were constructed to predict 5-year recurrence-free survival (RFS). Multivariate Cox regression analysis was used to identify independent risk factors for recurrence. RESULTS:Bladder, distant, and local recurrence rates at a mean of 56.19 ± 5.30 months after NU were 38.5%, 19.8%, and 7.9%, respectively. Univariate analysis showed that among the patients with bladder recurrence, female patients had significantly lower 5-year RFS than did male patients (34.7% ± 0.13% vs. 62.4% ± 0.06%, P = .038); however multivariate analysis showed that both female sex and a history of smoking were independent risk factors for bladder recurrence (odds ratio [OR], 4.22; 95% confidence interval [CI], 1.56-11.4; P = 0.005 and OR, 2.84; 95% CI, 1.1-7.4; P = .032, respectively). Univariate analysis showed that among the patients with local and distant recurrence, anemia, a positive history of bladder tumor, localization of the primary tumor, multiplicity, disease stage, and tumor grade significantly affected RFS, whereas primary tumor stage and grade were the only independent risk factors for 5-year RFS (OR, 4.48; 95% CI, 1.45-13.79; P = .009 and OR, 5.82; 95% CI, 2.08-16.26; P = .001, respectively). CONCLUSION:Female sex and a history of smoking were independent risk factors for bladder recurrence after NU. Such patients should be monitored closely using cystoscopy and urine cytologic examination. Invasive and higher grade UUT TCC was associated with worse local or systemic RFS.

journal_name

Clin Genitourin Cancer

authors

Gunay LM,Akdogan B,Koni A,Inci K,Bilen CY,Ozen H

doi

10.1016/j.clgc.2012.08.009

subject

Has Abstract

pub_date

2013-03-01 00:00:00

pages

39-44

issue

1

eissn

1558-7673

issn

1938-0682

pii

S1558-7673(12)00184-X

journal_volume

11

pub_type

杂志文章
  • Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 Study.

    abstract:BACKGROUND:Patients with biochemically recurrent prostate cancer and short prostate-specific antigen doubling time (PSADT) are at risk for metastasis yet may wish to avoid androgen deprivation therapy. Itraconazole may have antitumor activity without affecting circulating androgen levels. We therefore evaluated itracon...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2018.09.013

    authors: Lee M,Hong H,Kim W,Zhang L,Friedlander TW,Fong L,Lin AM,Small EJ,Wei XX,Rodvelt TJ,Miralda B,Stocksdale B,Ryan CJ,Aggarwal R

    更新日期:2019-02-01 00:00:00

  • Contemporary Incidence and Mortality Rates in Patients With Testicular Germ Cell Tumors.

    abstract:BACKGROUND:We comprehensively tested contemporary incidence and mortality rates in patients with germ cell tumor of the testis (GCTT). MATERIALS AND METHODS:Within the Surveillance, Epidemiology, and End Results database (2004-2015), statistical analyses included estimated annual percentage changes, multivariable logi...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.06.003

    authors: Palumbo C,Mistretta FA,Mazzone E,Knipper S,Tian Z,Perrotte P,Antonelli A,Montorsi F,Shariat SF,Saad F,Simeone C,Briganti A,Lattouf JB,Karakiewicz PI

    更新日期:2019-10-01 00:00:00

  • Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors.

    abstract:BACKGROUND:A rapid progression pattern called hyperprogressive disease (HPD) has been observed during early cycles of programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitor therapy. Data regarding HPD in patients with genitourinary cancer are limited. PATIENTS AND METHODS:We included 203 pa...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.09.009

    authors: Hwang I,Park I,Yoon SK,Lee JL

    更新日期:2020-04-01 00:00:00

  • Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma.

    abstract:BACKGROUND:There is a lack of molecularly-informed biomarkers for patients with metastatic renal cell carcinoma (RCC). Plasma cell-free DNA (cfDNA) sequencing is a minimally-invasive alternative to tissue for profiling the genome in other cancers but relevance in metastatic RCC remains unclear. MATERIALS AND METHODS:W...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.12.018

    authors: Bacon JVW,Annala M,Soleimani M,Lavoie JM,So A,Gleave ME,Fazli L,Wang G,Chi KN,Kollmannsberger CK,Wyatt AW,Nappi L

    更新日期:2020-08-01 00:00:00

  • Development of a Novel Prognostic Risk Score for Predicting Complications of Penectomy in the Surgical Management of Penile Cancer.

    abstract:INTRODUCTION:Penectomy for PC is useful in staging, disease prognosis, and treatment. Limited studies have evaluated its surgical complications. We sought to assess these complications and determine predictive models to create a novel risk score for penectomy complications. PATIENTS AND METHODS:A retrospective review ...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2018.09.018

    authors: Velazquez N,Press B,Renson A,Wysock JS,Taneja S,Huang WC,Bjurlin MA

    更新日期:2019-02-01 00:00:00

  • Survival After Partial Cystectomy for Variant Histology Bladder Cancer Compared With Urothelial Carcinoma: A Population-based Study.

    abstract:BACKGROUND:The present study tested cancer-specific (CSM) and overall mortality (OM) after partial cystectomy (PC) for variant histology bladder cancer (non-urothelial carcinoma of the urinary bladder UCUB), relative to UCUB and relative to radical cystectomy (RC). MATERIALS AND METHODS:Within the Surveillance, Epidem...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.10.016

    authors: Luzzago S,Palumbo C,Rosiello G,Knipper S,Pecoraro A,Deuker M,Mistretta FA,Tian Z,Musi G,Montanari E,Shariat SF,Saad F,Briganti A,de Cobelli O,Karakiewicz PI

    更新日期:2020-04-01 00:00:00

  • Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis.

    abstract:BACKGROUND:Results from large randomized controlled trials combining docetaxel, abiraterone, celecoxib, or bisphosphonates with androgen deprivation therapy (ADT) in hormone-sensitive prostate cancer have emerged. However, in our knowledge, few data are available in patients older than 70 years. Therefore, we undertook...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,meta分析

    doi:10.1016/j.clgc.2019.05.001

    authors: Landre T,Guetz GD,Chouahnia K,Fossey-Diaz V,Taleb C,Culine S

    更新日期:2019-08-01 00:00:00

  • Efficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient population.

    abstract:INTRODUCTION/BACKGROUND:Targeted therapy has become the mainstay of treatment for mRCC. The efficacy of this therapy in the older population is poorly understood. PATIENTS AND METHODS:Data from patients with mRCC treated with first-line anti-VEGF therapy were collected through the International mRCC Database Consortiu...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2014.02.009

    authors: Khambati HK,Choueiri TK,Kollmannsberger CK,North S,Bjarnason GA,Vaishampayan UN,Wood L,Knox JJ,Tan MH,MacKenzie MJ,Donskov F,Rini BI,Heng DY,International mRCC Database Consortium.

    更新日期:2014-10-01 00:00:00

  • Risk for Venous Thromboembolic Events in Patients With Advanced Urinary Tract Cancer Treated With First-Line Chemotherapy.

    abstract:BACKGROUND:Venous thromboembolic events (VTEs) frequently occur in cancer patients. Risk assessment models (RAMs) for cancer-associated thrombosis have been proposed. However, advanced urinary tract cancer (aUTC) was not adequately represented in these models. We studied the incidence of VTEs, the risk factors, and the...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.12.021

    authors: Bamias A,Tzannis K,Dimitriadis I,Tsironis G,Papatheorodidi AM,Tsiara A,Fragkoulis C,Xirokosta A,Barbarousi D,Papadopoulos G,Zakopoulou R,Varkarakis I,Mitsogiannis I,Adamakis I,Alamanis C,Stravodimos K,Papatsoris AG,Dell

    更新日期:2020-08-01 00:00:00

  • Darbepoetin alfa administered every 4 weeks for anemia in patients with advanced prostate cancer.

    abstract:PURPOSE:Anemia is a common morbidity of advanced prostate cancer, and prostate cancer treatment and has been associated with a worse overall survival and reduced quality of life in patients with prostate cancer. We sought to determine if infrequent dosing of darbepoetin alfa is safe and effective in treating anemia in ...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.3816/CGC.2007.n.012

    authors: Beer TM,Bergenstock M,Birt K,Higano CS

    更新日期:2007-06-01 00:00:00

  • Comparison of Laparoscopic and Robot-assisted Radical Cystectomy for Bladder Cancer: Perioperative and Oncologic Outcomes.

    abstract:BACKGROUND:The purpose of this study was to compare perioperative and oncologic outcomes between laparoscopic radical cystectomy (LRC) and robot-assisted radical cystectomy (RARC) for bladder cancer (BCa). MATERIALS AND METHODS:Patients who underwent LRC or RARC with curative intent for BCa between January 2011 and De...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.06.007

    authors: Su S,Gu L,Ma X,Li H,Wang B,Shi T,Zhang X

    更新日期:2019-10-01 00:00:00

  • The Incidence and Risk of Biochemical Recurrence Following Radical Radiotherapy for Prostate Cancer in Men on Angiotensin-Converting Enzyme Inhibitors (ACEIs) or Angiotensin Receptor Blockers (ARBs).

    abstract:BACKGROUND:Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are linked to prostate cancer, but their effect on biochemical recurrence (BR) remains unknown. Our aims were to investigate the incidence and risk of BR in men on ACEIs/ARBs after radical radiotherapy with adjuvant∖neo...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2016.03.009

    authors: Alashkham A,Paterson C,Windsor P,Struthers A,Rauchhaus P,Nabi G

    更新日期:2016-10-01 00:00:00

  • A phase II study of depsipeptide in refractory metastatic renal cell cancer.

    abstract:BACKGROUND:Therapeutic options for renal cell cancer are inadequate. Depsipeptide is a histone deacetylase inhibitor with promising preclinical and early clinical activity. PATIENTS AND METHODS:Patients with refractory renal cell cancer with normal organ function and no history of significant cardiovascular disease we...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,多中心研究

    doi:10.3816/CGC.2006.n.018

    authors: Stadler WM,Margolin K,Ferber S,McCulloch W,Thompson JA

    更新日期:2006-06-01 00:00:00

  • National trends in the recommendation of radiotherapy after prostatectomy for prostate cancer before and after the reporting of a survival benefit in March 2009.

    abstract:BACKGROUND:Three randomized trials demonstrated that postprostatectomy adjuvant radiotherapy improves biochemical disease-free survival for patients with adverse pathologic features, and 1 trial found adjuvant radiotherapy improves overall survival. We sought to determine whether postprostatectomy radiotherapy (PPRT) u...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2014.12.005

    authors: Mahal BA,Hoffman KE,Efstathiou JA,Nguyen PL

    更新日期:2015-06-01 00:00:00

  • A Combination of Cisplatin and 5-Fluorouracil With a Taxane in Patients Who Underwent Lymph Node Dissection for Nodal Metastases From Squamous Cell Carcinoma of the Penis: Treatment Outcome and Survival Analyses in Neoadjuvant and Adjuvant Settings.

    abstract:BACKGROUND:The role of chemotherapy in nodal metastases from penile squamous cell carcinoma is not defined. We evaluated the efficacy of a combination of T-PF (a taxane, cisplatin, and 5-fluorouracil) in neoadjuvant and adjuvant settings. PATIENTS AND METHODS:Since June of 2004, T-PF was administered to stage N2 to 3 ...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2015.07.009

    authors: Nicolai N,Sangalli LM,Necchi A,Giannatempo P,Paganoni AM,Colecchia M,Piva L,Catanzaro MA,Biasoni D,Stagni S,Torelli T,Raggi D,Faré E,Pizzocaro G,Salvioni R

    更新日期:2016-08-01 00:00:00

  • Clinical and Molecular Characteristics and Burden of Kidney Cancer Among Hispanics and Native Americans: Steps Toward Precision Medicine.

    abstract::Cancer disparities in Native Americans (NAs) and Hispanic Americans (HAs) vary significantly in terms of cancer incidence and mortality rates across geographic regions. This review reports that kidney and renal pelvis cancers are unevenly affecting HAs and NAs compared to European Americans of non-Hispanic origin, and...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clgc.2018.01.006

    authors: Batai K,Bergersen A,Price E,Hynes K,Ellis NA,Lee BR

    更新日期:2018-06-01 00:00:00

  • Nucleolin Staining May Aid in the Identification of Circulating Prostate Cancer Cells.

    abstract:INTRODUCTION:Circulating tumor cells (CTCs) have great potential as circulating biomarkers for solid malignancies. Currently available assays for CTC detection rely on epithelial markers with somewhat limited sensitivity and specificity. We found that the staining pattern of nucleolin, a common nucleolar protein in pro...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2016.12.004

    authors: Chalfin HJ,Verdone JE,van der Toom EE,Glavaris S,Gorin MA,Pienta KJ

    更新日期:2017-06-01 00:00:00

  • Sociodemographic Disparities in the Nonoperative Management of Small Renal Masses.

    abstract:BACKGROUND:Local tumor ablation (LTA) and expectant management (EM) represent competing treatment modalities for patients with small renal masses (SRMs) who are unfit for surgery. We examined the potential social discrepancies in the access of LTA and EM. MATERIALS AND METHODS:A total of 1860 patients with cT1a kidney...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2015.10.011

    authors: Trudeau V,Larcher A,Sun M,Boehm K,Dell'Oglio P,Meskawi M,Sosa J,Tian Z,Fossati N,Briganti A,Karakiewicz PI

    更新日期:2016-04-01 00:00:00

  • Phase II study of azacitidine to restore responsiveness of prostate cancer to hormonal therapy.

    abstract::Epigenetic alterations, including methylation of key tumor suppressor genes, may play a role in the progression of prostate cancer to a castration-refractory state. Azacitidine, an agent approved for the treatment of myelodysplastic syndromes, appears to exert its antineoplastic effects partly by hypomethylating DNA t...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.3816/CGC.2007.n.036

    authors: Sonpavde G,Aparicio A,Guttierez I,Boehm KA,Hutson TE,Berry WR,Asmar L,von Hoff DD

    更新日期:2007-12-01 00:00:00

  • What Have Patients Been Hearing From Providers Since the 2012 USPSTF Recommendation Against Routine Prostate Cancer Screening?

    abstract:BACKGROUND:In this study we aimed to determine the relationship between prostate-specific antigen (PSA)-related information obtained from the provider and PSA test uptake. With recent focus on patient-provider communication (PC) and the guidelines recommending against PSA tests for prostate cancer (PCa), PC regarding t...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2017.05.002

    authors: Haider MR,Qureshi ZP,Horner R,Friedman DB,Bennett C

    更新日期:2017-12-01 00:00:00

  • Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies.

    abstract:BACKGROUND:Everolimus is an approved agent for use after disease progression with vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) in patients with metastatic renal cell carcinoma. With recently published trials showing efficacy of nivolumab and cabozantinib in the second-line therapy...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2015.12.011

    authors: Patel SB,Stenehjem DD,Gill DM,Tantravahi SK,Agarwal AM,Hsu J,Vuong W,Pal SK,Agarwal N

    更新日期:2016-04-01 00:00:00

  • Influence of body mass index and smoking on the long-term survival of patients with renal cell cancer.

    abstract:BACKGROUND:Smoking and obesity are known risk factors for renal cell carcinoma (RCC). We determined the influence of smoking, body mass index (BMI), and symptoms on the survival of patients with RCC. PATIENTS AND METHODS:In this retrospective study, the relative overall survival (OS) up to 25 years was calculated amon...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2013.04.017

    authors: Sunela KL,Kataja MJ,Kellokumpu-Lehtinen PL

    更新日期:2013-12-01 00:00:00

  • Risk-Stratified Initial Salvage Therapy for Relapsed or Refractory Metastatic Germ Cell Tumors.

    abstract:BACKGROUND:Salvage treatment with either conventional-dose chemotherapy (CDCT) or high-dose chemotherapy with autologous stem cell transplantation (HDCT) offers curative potential for patients with relapsed or refractory germ cell tumor (GCT). However, the optimal initial salvage strategy remains controversial, and the...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2016.03.015

    authors: Narayan V,Gunnarsson O,Hwang WT,Squillante CM,Nathanson KL,Stadtmauer EA,Vaughn DJ

    更新日期:2016-12-01 00:00:00

  • Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma.

    abstract:OBJECTIVE:Second-line systemic therapy for advanced urothelial carcinoma (UC) has substantial unmet needs, and current agents show dismal activity. Second-line trials of metastatic UC have used response rate (RR) and median progression-free survival (PFS) as primary endpoints, which may not reflect durable benefits. A ...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,meta分析

    doi:10.1016/j.clgc.2013.09.002

    authors: Agarwal N,Bellmunt J,Maughan BL,Boucher KM,Choueiri TK,Qu AQ,Vogelzang NJ,Fougeray R,Niegisch G,Albers P,Wong YN,Ko YJ,Sridhar SS,Tantravahi SK,Galsky MD,Petrylak DP,Vaishampayan UN,Mehta AN,Beer TM,Sternberg CN,R

    更新日期:2014-04-01 00:00:00

  • Phase II open-label study of oral piritrexim in patients with advanced carcinoma of the urothelium who have experienced failure with standard chemotherapy.

    abstract:BACKGROUND:Piritrexim is reported to have a response rate of 38% in patients with chemotherapy-naive disease and 23% for second-line therapy after chemotherapy failure. We report the results of a multiinstitutional, open-label, 2-stage, phase II study that further evaluates oral piritrexim in patients with urothelial c...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,多中心研究

    doi:10.3816/CGC.2008.n.005

    authors: Lassiter LK,Tummala MK,Hussain MH,Stadler WM,Petrylak DP,Carducci MA

    更新日期:2008-03-01 00:00:00

  • Comparative Effectiveness of Intravesical BCG-Tice and BCG-Moreau in Patients With Non-muscle-invasive Bladder Cancer.

    abstract:BACKGROUND:The purpose of this study was to compare the efficacy of 2 bacillus Calmette-Guérin (BCG) strains, BCG-Tice and BCG-Moreau, in the treatment of non-muscle-invasive bladder cancer (NMIBC). MATERIALS AND METHODS:We retrospectively reviewed clinical data from patients treated with BCG for NMIBC at 3 academic c...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.clgc.2019.10.021

    authors: D'Andrea D,Soria F,Abufaraj M,Pones M,Gontero P,Machado AT,Waksman R,Enikeev DV,Glybochko PV,Adonias SP,Nahas WC,Shariat SF,Chade DC

    更新日期:2020-02-01 00:00:00

  • Perinephric and Sinus Fat Invasion in Stage pT3a Tumors Managed by Partial Nephrectomy.

    abstract:INTRODUCTION:We evaluated the influence of perinephric fat invasion (PFI) compared with sinus fat invasion (SFI) on disease-free survival (DFS) and cancer-specific survival (CSS) after partial nephrectomy (PN) for stage pT3a renal cell carcinoma (RCC). MATERIALS AND METHODS:Data were recorded from the consecutive reco...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2017.07.019

    authors: Mouracade P,Dagenais J,Chavali JS,Kara O,Nelson RJ,Maurice MJ,Reese J,Rini BI,Kaouk JH

    更新日期:2018-10-01 00:00:00

  • Phase II trial of sunitinib for the therapy of progressive metastatic castration-refractory prostate cancer after previous docetaxel chemotherapy.

    abstract::Effective options are lacking for progressive castration-refractory prostate cancer (CRPC) after conventional chemotherapy. Sunitinib is an orally administered multitargeted tyrosine kinase inhibitor that is approved multinationally for renal cell carcinoma and gastrointestinal stromal tumors. A phase II trial was con...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,多中心研究

    doi:10.3816/CGC.2008.n.023

    authors: Sonpavde G,Hutson TE,Berry WR,Boehm KA,Asmar L

    更新日期:2008-09-01 00:00:00

  • Cyclooxygenase-2: a therapeutic target for prostate cancer.

    abstract::The discovery and elucidation of prostaglandin (PG) pathways, particularly the molecular and clinical role of cyclooxygenase-2 (COX-2) function, has been found to have an important role in neoplasia. Current understanding of the role of COX-2 activity and therefore the potential clinical usefulness of COX-2-specific i...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,评审

    doi:10.3816/CGC.2005.n.034

    authors: Pruthi RS,Wallen EM

    更新日期:2005-12-01 00:00:00

  • Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials.

    abstract:BACKGROUND:Hyperglycemia and hypercholesterolemia are class effects of mammalian target of rapamycin inhibitors. The purpose of this study was to characterize safety and efficacy of patients with metastatic renal cell carcinoma (mRCC) treated with everolimus in RECORD-1 (REnal Cell cancer treatment with Oral RAD001 giv...

    journal_title:Clinical genitourinary cancer

    pub_type: 临床试验,杂志文章

    doi:10.1016/j.clgc.2016.04.011

    authors: Bono P,Oudard S,Bodrogi I,Hutson TE,Escudier B,Machiels JP,Thompson JA,Figlin RA,Ravaud A,Basaran M,Porta C,Bracarda S,Brechenmacher T,Lin C,Voi M,Grunwald V,Motzer RJ

    更新日期:2016-10-01 00:00:00